These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Comparison of antithrombotic strategies in patients with cryptogenic stroke and patent foramen ovale: an updated meta-analysis. Angelini F; Fortuni F; Tsivgoulis G; Agnelli G; Bocchino PP; Franchin L; De Filippo O; Bellettini M; D'Ascenzo F; Crimi G; Leonardi S; De Ferrari GM; Paciaroni M Cardiovasc Drugs Ther; 2021 Oct; 35(5):987-993. PubMed ID: 32918655 [TBL] [Abstract][Full Text] [Related]
23. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials. Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192 [TBL] [Abstract][Full Text] [Related]
24. Recurrent Stroke Reduction with Patent Foramen Ovale Closure versus Medical Therapy Based on Patent Foramen Ovale Characteristics: A Meta-Analysis of Randomized Controlled Trials. Garg A; Thawabi M; Rout A; Sossou C; Cohen M; Kostis JB Cardiology; 2019; 144(1-2):40-49. PubMed ID: 31574522 [TBL] [Abstract][Full Text] [Related]
35. Secondary prevention of cryptogenic stroke in patients with patent foramen ovale: a systematic review and meta-analysis. Fiorelli EM; Carandini T; Gagliardi D; Bozzano V; Bonzi M; Tobaldini E; Comi GP; Scarpini EA; Montano N; Solbiati M Intern Emerg Med; 2018 Dec; 13(8):1287-1303. PubMed ID: 30032341 [TBL] [Abstract][Full Text] [Related]
36. [Embolic stroke of undetermined source]. Vinogradov OI; Jablonskij MA; Kuznecov AN Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(12. Vyp. 2):42-48. PubMed ID: 33449532 [TBL] [Abstract][Full Text] [Related]
37. A meta-analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events. Pineda AM; Nascimento FO; Yang SC; Kirtane AJ; Sommer RJ; Beohar N Catheter Cardiovasc Interv; 2013 Nov; 82(6):968-75. PubMed ID: 23832613 [TBL] [Abstract][Full Text] [Related]
38. Is Patent Foramen Ovale Closure More Effective Than Medical Therapy in Preventing Stroke Recurrence in Patients With Cryptogenic Stroke?: A Critically Appraised Topic. Valencia-Sanchez C; Fortuin FD; Sweeney JP; Ingall TJ; Marks LA; Wingerchuk DM; O'Carroll CB Neurologist; 2018 Sep; 23(5):175-180. PubMed ID: 30169372 [TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials. Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616 [TBL] [Abstract][Full Text] [Related]
40. Updates in the Management of Cryptogenic Stroke and Patent Foramen Ovale. Stone DK; Buchwald N; Wilson CA J Neuroophthalmol; 2020 Mar; 40(1):60-66. PubMed ID: 31996589 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]